Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Target Price at $12.25

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been assigned an average recommendation of “Moderate Buy” from the fifteen analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $12.25.

A number of research analysts have recently weighed in on CMPX shares. Canaccord Genuity Group dropped their price target on Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Friday, July 17th. Raymond James Financial cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 28th. Wall Street Zen downgraded shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Citizens Jmp restated a “market outperform” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Tuesday, April 28th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CMPX. Vivo Capital LLC increased its position in Compass Therapeutics by 57.9% during the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock worth $33,409,000 after buying an additional 3,502,000 shares in the last quarter. BVF Inc. IL lifted its position in shares of Compass Therapeutics by 63.5% in the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock valued at $41,697,000 after acquiring an additional 3,014,842 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Compass Therapeutics during the third quarter valued at $9,892,000. Braidwell LP acquired a new stake in shares of Compass Therapeutics during the fourth quarter valued at $14,965,000. Finally, Millennium Management LLC increased its position in Compass Therapeutics by 280.4% during the 3rd quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock worth $11,332,000 after purchasing an additional 2,386,367 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Price Performance

CMPX opened at $2.12 on Tuesday. Compass Therapeutics has a 1-year low of $1.61 and a 1-year high of $6.88. The stock has a market cap of $381.79 million, a P/E ratio of -5.17 and a beta of 0.90. The stock’s 50 day simple moving average is $2.11 and its 200 day simple moving average is $4.12.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Research analysts expect that Compass Therapeutics will post -0.42 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.